Cargando…
组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展
Immunotherapy is one of the main strategies of anti-tumor therapy at present, in which immune checkpoint inhibitors (ICIs) are the most widely used drug. ICIs resistance is mediated by a variety of cytokines and immune cells, and the mechanism is complex, which is the main reason for the failure of...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143971/ https://www.ncbi.nlm.nih.gov/pubmed/33819971 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.11 |
_version_ | 1783696864978141184 |
---|---|
collection | PubMed |
description | Immunotherapy is one of the main strategies of anti-tumor therapy at present, in which immune checkpoint inhibitors (ICIs) are the most widely used drug. ICIs resistance is mediated by a variety of cytokines and immune cells, and the mechanism is complex, which is the main reason for the failure of immunotherapy in cancer patients. Histone deacetylase inhibitor (HDACi), as a class of epigenetic regulatory drugs, plays an important role in regulating cell cycle, proliferation, differentiation, and activity. In recent years, Studies have found that HDACi can not only regulate cell biological characteristics, but also closely related to the improvement of tumor ICIs drug resistance. Therefore, the study on how HDACi enhances the efficacy of ICIs is of great significance to tumor immunotherapy. This article will review the research progress of HDACi combined with ICIs in treating malignant tumors and their related mechanism. |
format | Online Article Text |
id | pubmed-8143971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-81439712021-05-26 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展 Zhongguo Fei Ai Za Zhi 综述 Immunotherapy is one of the main strategies of anti-tumor therapy at present, in which immune checkpoint inhibitors (ICIs) are the most widely used drug. ICIs resistance is mediated by a variety of cytokines and immune cells, and the mechanism is complex, which is the main reason for the failure of immunotherapy in cancer patients. Histone deacetylase inhibitor (HDACi), as a class of epigenetic regulatory drugs, plays an important role in regulating cell cycle, proliferation, differentiation, and activity. In recent years, Studies have found that HDACi can not only regulate cell biological characteristics, but also closely related to the improvement of tumor ICIs drug resistance. Therefore, the study on how HDACi enhances the efficacy of ICIs is of great significance to tumor immunotherapy. This article will review the research progress of HDACi combined with ICIs in treating malignant tumors and their related mechanism. 中国肺癌杂志编辑部 2021-03-20 /pmc/articles/PMC8143971/ /pubmed/33819971 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.11 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https: //creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) . |
spellingShingle | 综述 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展 |
title | 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展 |
title_full | 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展 |
title_fullStr | 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展 |
title_full_unstemmed | 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展 |
title_short | 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展 |
title_sort | 组蛋白去乙酰化酶抑制剂联合免疫检查点抑制剂治疗肿瘤的研究进展 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143971/ https://www.ncbi.nlm.nih.gov/pubmed/33819971 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.11 |
work_keys_str_mv | AT zǔdànbáiqùyǐxiānhuàméiyìzhìjìliánhémiǎnyìjiǎnchádiǎnyìzhìjìzhìliáozhǒngliúdeyánjiūjìnzhǎn AT zǔdànbáiqùyǐxiānhuàméiyìzhìjìliánhémiǎnyìjiǎnchádiǎnyìzhìjìzhìliáozhǒngliúdeyánjiūjìnzhǎn AT zǔdànbáiqùyǐxiānhuàméiyìzhìjìliánhémiǎnyìjiǎnchádiǎnyìzhìjìzhìliáozhǒngliúdeyánjiūjìnzhǎn |